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ABSTRACT
Radiation biology is being transformed by the implementation of small animal image-guided precision radiotherapy into
pre-clinical research programmes worldwide. We report on the current status and developments of the small animal
radiotherapy field, suggest criteria for the design and execution of effective studies and contend that this powerful
emerging technology, used in combination with relevant small animal models, holds much promise for translational
impact in radiation oncology.
STATUS
Over the past two decades, signiﬁcant advances in radio-
therapy technology have enabled increasingly sophisticated
methods for treatment planning, delivery and imaging to
be implemented into routine radiation oncology practice.
As such, innovations in radiotherapy can be attributed
primarily to technological developments rather than a
more comprehensive understanding of the radiobiology
underpinning responses in tumour and normal tissue that
can be achieved through validation in animal models.
Accurate simulation of the spatial and temporal complexity
of dose typically delivered during contemporary radio-
therapy techniques, such as intensity-modulated radiotherapy,
is likely to facilitate a more thorough understanding of the
biological basis of tissue responses to radiotherapy.
The recent development and commercialization of small
animal image-guided radiotherapy devices is revolutioniz-
ing radiobiology research. Researchers are now empow-
ered to conduct pre-clinical investigations in a manner
that more accurately reﬂects the clinical scenario using
millimetre-sized beams under precision cone beam CT (CBCT)
image guidance.1 The technology has much potential to
address some of the current outstanding challenges in ra-
diation oncology towards biological individualization, dose
painting, adaptive radiotherapy and synergy with other
treatment modalities. These were topics for discussion at
the second symposium on precision image-guided small
animal radiotherapy held recently from 11 to 13 August
2014 at the University of British Columbia, Vancouver,
Canada.2
In addition to research reports from investigators around
the world, the system manufacturers who share the small
animal radiotherapy market also showcased their on-
going developments for their respective systems, the
Xstrahl Life Sciences (Camberly, UK), Small Animal
Radiation Research Platform, and the Precision X-ray
Inc. (North Branford, CT), X-RAD 225Cx. Both systems
are offering integrated precision irradiation with CBCT
guidance and bioluminescence tomography for im-
proved targeting and longitudinal response monitoring.
They also offer treatment planning systems with dose
calculation tools based on advanced superposition con-
volution (Muriplan from Xstrahl Life Sciences) or Monte
Carlo methods (SmART-Plan from Precision X-ray Inc.).3,4
Both companies continue to focus developments on
more accurately reproducing the clinical scenario.
Xstrahl, in collaboration with researchers at the Johns
Hopkins University, Baltimore, MD, has developed a mo-
torized variable radiation ﬁeld collimator that will poten-
tially allow delivery of intensity-modulated beams and
a motion compensation shutter for beam gating during the
respiratory cycle. Precision X-ray Inc., in collaboration
with researchers at the University of Toronto, Toronto, ON,
Canada, and the Maastro Clinic, Maastricht, Netherlands,
is developing inverse dose planning techniques to allow
delivery of more complex dose distributions with ease.
CONSIDERATIONS
The implementation of small animal radiotherapy into labora-
tory practice is essentially deﬁning the emerging discipline of
pre-clinical radiotherapy; allowing in vivo radiobiological studies
to be performed in a manner highly analogous to clinical prac-
tice. A major challenge now facing investigators in the ﬁeld is
how to correctly apply the technology using relevant small an-
imal models so that it can be leveraged to address the pertinent
outstanding problems in radiation oncology. To do so effectively,
a number of important criteria should be considered and ap-
plied to hypothesis-driven investigations using small animal
radiotherapy. These criteria include:
Multidisciplinary study design and high-quality
assurance
In the same way that the best course of treatment for a patient is
determined through a multidisciplinary team meeting, pre-
clinical investigations should be designed in a similar manner
involving discussions between biologists, physicists and clinicians.
A team-based approach will ensure that relevant strategies are
adopted early in the design of studies, maximizing the potential
for successful execution in the laboratory. Similar to radiotherapy
in humans, irradiation of small animals should also be subject to
strict quality assurance protocols. Beam accuracy can be veriﬁed
using the on-board imaging devices that have shown small animal
radiotherapy treatment plans to be delivered according to pre-
scription within an uncertainty of 5% for beams as small as 4mm
in diameter.5 However, there are currently no systematic quality
assurance standards for pre-clinical radiotherapy, an area of con-
cern being addressed internationally by the National Institute of
Standards and Technology, the American Association of Physicists
in Medicine and the National Cancer Research Institute Clinical
and Translational Radiotherapy Research working groups.
Biologically relevant processes that mimic
human conditions
Small animal radiotherapy studies should use models that are
biologically relevant and that as far as possible recapitulate the
physiological and pathological features of the clinical condition
in humans. Tumour models established either spontaneously by
mouse genome editing approaches or by xenografting have re-
spective merits depending on the aims of the investigation.6
Whilst orthotopic implantation is more technically challenging,
it is signiﬁcantly more representative of tumour biology than
grafting to ectopic sites, particularly in the context of the tu-
mour microenvironment. Irrespective of how an experimental
model is established, it should be used with pre-deﬁned, clini-
cally relevant end points that will provide the data necessary to
test key research hypotheses. Furthermore, it may be necessary
to use several complementary models that focus on different
aspects of underlying biological processes before drawing accu-
rate evidence-based conclusions from a study.
Clinically relevant doses and fractionation schedule
Deﬁning the dose–response relationship for tumour and normal
tissues in mice is challenging. Classical radiobiological studies
used the LD50/30 end point, deﬁned as the radiation dose
resulting in death or survival of 50% of animals within 30 days.
However, these measures may be confounded by both genetic
(e.g. strain variation) and non-genetic factors (e.g. age, husbandry,
microbial status). The human population is also heterogeneous in
terms of radiosensitivity; therefore, direct comparison between
mice and humans with certainty is difﬁcult owing to multiple
confounding factors. However, it is generally believed that dose
effects in mice and humans are in fact comparable and so clini-
cally relevant doses should be delivered in mice. The capability of
precision guidance now enables the delivery of multiple fractions
and so studies can deliver clinically relevant treatments in terms of
both dose and fractionation schedule.
Relevance to human radiotherapy trials
The goal of pre-clinical radiotherapy studies is ultimately to
translate discovery through human trials, therefore, pre-clinical
radiotherapy studies should be designed to align with Phase 1
trials. Furthermore, small animal radiotherapy studies can be
performed in parallel with human trials to gain de novo mech-
anistic insight into trial outcomes, an intriguing concept recently
described by Abate-Shen and Pandolﬁ7 for translational in-
tegration of mouse and human trials. The capacity to model
human radiotherapy trials in mice is not a trivial task but has
much potential to provide further radiobiological understand-
ing and improve the basis upon which trials in humans are
designed.
The above criteria highlight some of the important consid-
erations for the design of effective small animal radiotherapy
studies. These criteria are not comprehensive in scope, as there
are many additional biological and technical issues to consider
including choice of anaesthesia, number of animals needed to
ensure statistical power in conclusions and the technical work-
ﬂow from treatment planning through to tissue collection that
should be considered when designing small animal radiotherapy
studies.
POTENTIAL FOR TRANSLATIONAL IMPACT
Mouse models have been used extensively as the model of choice
for pre-clinical research, as they share anatomical and genetic
similarities with humans,8 yet, only about a third of highly cited
animal studies have translated at the level of human randomized
trials.9 In the context of radiotherapy clinical trials, patients
recruited to experimental arms often may not have improved
outcomes compared with the standard of care.10 The reasons for
these negative outcomes and the possible solutions to improve
radiotherapy trials have been identiﬁed through the Radiation
Research Programme of the National Cancer Institute.11 Robust
pre-clinical data accompanied with translational strategies are
key factors to improving radiotherapy trial outcomes. Small
animal radiotherapy offers the capacity to improve pre-clinical
studies that will in turn facilitate better approaches for trans-
lation. In addition, there is a need for much collaboration across
research centres, which may be best implemented through an
international network to co-ordinate efforts and reduce the
timeframe and associated research costs for translational
development.
Despite the challenges, small animal radiotherapy has potential
to bridge the translational gap between basic radiobiology and
radiotherapy and presents a promising future. Pre-clinical data
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in small animals must be interpreted correctly and with due
consideration of the limitations. As researchers gain conﬁdence
in their roles as multidisciplinary scientists, pre-clinical studies
will increasingly replicate the clinical scenario with unprec-
edented accuracy, driving new approaches in radiobiology that
will ultimately translate to human health gains.
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